Faeth Therapeutics, Inc. (FTH): who owns it and who trades it
As of Nov 16, 2026, FTH insiders reported 36 open-market sales worth $1.5M and 49 purchases worth $2.5M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Cambrian BioPharma Inc (10% owner), with $788K. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Faeth Therapeutics
From the latest filingsOverall: more buying than selling. Funds and famous investors mostly bought. Insiders was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns FTH
44 funds and institutions reported FTH shares worth $326M at the end of Q2 2026, about 50% of the company. The largest holder is Montanova Capital, LLC with 7.8%.
Funds and institutions (13F) 50%Everyone else 50%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Montanova Capital, LLC | 2.02M | 7.82% | $50.5M | +5747% |
| Avoro Capital Advisors LLC | 1.44M | 5.59% | $36.1M | New |
| Baker Bros. Advisors LP | 1.29M | 4.98% | $32.2M | New |
| Balyasny Asset Management L.P. | 1.04M | 4.03% | $26.1M | +6331% |
| Ra Capital Management, L.P. | 722,020 | 2.79% | $18.1M | New |
| Vivo Capital, LLC | 722,020 | 2.79% | $18.1M | No change |
| Logos Global Management LP | 722,020 | 2.79% | $18.1M | +2307% |
| Fairmount Funds Management LLC | 722,020 | 2.79% | $18.1M | New |
| Caligan Partners LP | 629,467 | 2.44% | $15.7M | +400% |
| B Group, Inc. | 610,169 | 2.36% | $15.3M | New |
| Trails Edge Capital Partners, LP | 515,335 | 1.99% | $12.9M | +312% |
| Franklin Resources Inc | 494,516 | 1.91% | $12.4M | +270% |
| ADAR1 Capital Management, LLC | 361,010 | 1.40% | $9M | New |
| Octagon Capital Advisors LP | 361,010 | 1.40% | $9M | New |
| Marshall Wace, LLP | 206,508 | 0.80% | $5.2M | +214% |
| Boxer Capital Management, LLC | 180,505 | 0.70% | $4.5M | New |
| Patient Square Capital LP | 175,050 | 0.68% | $4.4M | New |
| Alyeska Investment Group, L.P. | 144,404 | 0.56% | $3.6M | New |
| Affinity Asset Advisors, LLC | 144,404 | 0.56% | $3.6M | New |
| Boothbay Fund Management, LLC | 133,643 | 0.52% | $3.3M | +412% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, FTH insiders reported $2.5M of open-market purchases and $1.5M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | Brian C Stephenson | CFO | Purchase | 600 | $24.22 | $14.5K | Form 4 |
| Jul 1, 2026 | Brian C Stephenson | CFO | Purchase | 4,400 | $23.40 | $103K | Form 4 |
| Jun 30, 2026 | Brian C Stephenson | CFO | Purchase | 1,638 | $23.88 | $39.1K | Form 4 |
| Jun 30, 2026 | Brian C Stephenson | CFO | Purchase | 1,910 | $22.95 | $43.8K | Form 4 |
| Jun 30, 2026 | Brian C Stephenson | CFO | Purchase | 4,255 | $24.98 | $106K | Form 4 |
| Jun 29, 2026 | Brian C Stephenson | CFO | Purchase | 831 | $23.34 | $19.4K | Form 4 |
| Jun 26, 2026 | Brian C Stephenson | CFO | Purchase | 100 | $26.39 | $2.6K | Form 4 |
| Jun 26, 2026 | Brian C Stephenson | CFO | Purchase | 1,358 | $25.55 | $34.7K | Form 4 |
| Jun 26, 2026 | Brian C Stephenson | CFO | Purchase | 4,212 | $24.90 | $105K | Form 4 |
| Jun 26, 2026 | Brian C Stephenson | CFO | Purchase | 580 | $23.61 | $13.7K | Form 4 |
| Jun 24, 2026 | Brian C Stephenson | CFO | Purchase | 100 | $27.77 | $2.8K | Form 4 |
| Jun 24, 2026 | Brian C Stephenson | CFO | Purchase | 3,400 | $26.98 | $91.7K | Form 4 |
| Jun 24, 2026 | Brian C Stephenson | CFO | Purchase | 3,000 | $25.98 | $77.9K | Form 4 |
| Jun 24, 2026 | Brian C Stephenson | CFO | Purchase | 2,891 | $25.22 | $72.9K | Form 4 |
| Jun 23, 2026 | Brian C Stephenson | CFO | Purchase | 6,836 | $24.12 | $165K | Form 4 |
| Jun 23, 2026 | Brian C Stephenson | CFO | Purchase | 1,969 | $24.84 | $48.9K | Form 4 |
| Jun 23, 2026 | Brian C Stephenson | CFO | Purchase | 425 | $25.91 | $11K | Form 4 |
| Jun 22, 2026 | Brian C Stephenson | CFO | Purchase | 1,118 | $20.82 | $23.3K | Form 4 |
| Jun 22, 2026 | Brian C Stephenson | CFO | Purchase | 1,583 | $22.40 | $35.5K | Form 4 |
| Jun 22, 2026 | Brian C Stephenson | CFO | Purchase | 3,329 | $23.28 | $77.5K | Form 4 |
| Jun 22, 2026 | Brian C Stephenson | CFO | Purchase | 356 | $23.95 | $8.5K | Form 4 |
| Jun 22, 2026 | Brian C Stephenson | CFO | Purchase | 1,797 | $20.23 | $36.4K | Form 4 |
| Jun 22, 2026 | Anand Kiran Parikh | CEO | Purchase | 2,806 | $19.76 | $55.4K | Form 4 |
| Jun 1, 2026 | Cambrian BioPharma Inc | 10% owner | Sale | 24,524 | $20.00 | $490K | Form 4 |
| Jun 1, 2026 | Cambrian BioPharma Inc | 10% owner | Sale | 476 | $21.14 | $10.1K | Form 4 |
| Apr 7, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Purchase | 1,108 | $33.38 | $37K | Form 4 |
| Apr 7, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Sale | 2,115 | $28.94 | $61.2K | Form 4 |
| Apr 7, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Sale | 205 | $29.71 | $6.1K | Form 4 |
| Apr 7, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Sale | 4,423 | $31.38 | $139K | Form 4 |
| Apr 7, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Sale | 300 | $32.25 | $9.7K | Form 4 |
| Apr 7, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Sale | 1,108 | $33.38 | $37K | Form 4 |
| Apr 6, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Sale | 45 | $31.96 | $1.4K | Form 4 |
| Apr 6, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Sale | 1,214 | $31.02 | $37.7K | Form 4 |
| Apr 6, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Purchase | 1,104 | $31.02 | $34.2K | Form 4 |
| Apr 2, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Sale | 1,134 | $34.80 | $39.5K | Form 4 |
| Apr 2, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Sale | 374 | $33.35 | $12.5K | Form 4 |
| Apr 2, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Sale | 1,794 | $32.60 | $58.5K | Form 4 |
| Apr 2, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Sale | 1,265 | $31.75 | $40.2K | Form 4 |
| Apr 2, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Sale | 3,099 | $30.86 | $95.6K | Form 4 |
| Apr 2, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Purchase | 1,276 | $34.75 | $44.3K | Form 4 |
| Apr 2, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Purchase | 26 | $33.47 | $870 | Form 4 |
| Apr 2, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Purchase | 701 | $35.55 | $24.9K | Form 4 |
| Apr 1, 2026 | Millennium Management Llc +3 | 10% owner | Purchase | 1,613 | $34.59 | $55.8K | Form 4 |
| Apr 1, 2026 | Millennium Management Llc +3 | 10% owner | Purchase | 1,161 | $31.53 | $36.6K | Form 4 |
| Apr 1, 2026 | Millennium Management Llc +3 | 10% owner | Sale | 46 | $34.75 | $1.6K | Form 4 |
| Apr 1, 2026 | Millennium Management Llc +3 | 10% owner | Sale | 1,104 | $31.52 | $34.8K | Form 4 |
| Apr 1, 2026 | Millennium Management Llc +3 | 10% owner | Purchase | 3,401 | $35.46 | $121K | Form 4 |
| Mar 31, 2026 | Millennium Management Llc +3 | 10% owner | Purchase | 186 | $30.48 | $5.7K | Form 4 |
| Mar 31, 2026 | Millennium Management Llc +3 | 10% owner | Purchase | 616 | $24.69 | $15.2K | Form 4 |
| Mar 31, 2026 | Millennium Management Llc +3 | 10% owner | Purchase | 1,770 | $25.32 | $44.8K | Form 4 |
| Mar 31, 2026 | Millennium Management Llc +3 | 10% owner | Purchase | 1,048 | $26.73 | $28K | Form 4 |
| Mar 31, 2026 | Millennium Management Llc +3 | 10% owner | Purchase | 17 | $27.78 | $472 | Form 4 |
| Mar 31, 2026 | Millennium Management Llc +3 | 10% owner | Purchase | 1,957 | $31.45 | $61.5K | Form 4 |
| Mar 31, 2026 | Millennium Management Llc +3 | 10% owner | Purchase | 411 | $32.60 | $13.4K | Form 4 |
| Mar 31, 2026 | Millennium Management Llc +3 | 10% owner | Sale | 191 | $24.28 | $4.6K | Form 4 |
| Mar 31, 2026 | Millennium Management Llc +3 | 10% owner | Sale | 1,251 | $25.17 | $31.5K | Form 4 |
| Mar 31, 2026 | Millennium Management Llc +3 | 10% owner | Sale | 57 | $27.11 | $1.5K | Form 4 |
| Mar 31, 2026 | Millennium Management Llc +3 | 10% owner | Sale | 5 | $28.41 | $142 | Form 4 |
| Mar 31, 2026 | Millennium Management Llc +3 | 10% owner | Sale | 87 | $31.52 | $2.7K | Form 4 |
| Mar 30, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Sale | 518 | $25.85 | $13.4K | Form 4 |
| Mar 30, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Sale | 370 | $27.68 | $10.2K | Form 4 |
| Mar 30, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Purchase | 2,992 | $25.08 | $75K | Form 4 |
| Mar 30, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Purchase | 4,995 | $25.99 | $130K | Form 4 |
| Mar 30, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Purchase | 1,176 | $26.70 | $31.4K | Form 4 |
| Mar 30, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Purchase | 370 | $27.68 | $10.2K | Form 4 |
| Mar 27, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Purchase | 10,643 | $26.29 | $280K | Form 4 |
| Mar 27, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Purchase | 4,384 | $27.28 | $120K | Form 4 |
| Mar 27, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Purchase | 294 | $28.13 | $8.3K | Form 4 |
| Mar 27, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Sale | 469 | $26.77 | $12.6K | Form 4 |
| Mar 27, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Sale | 36 | $27.37 | $985 | Form 4 |
| Mar 26, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Purchase | 1,327 | $27.95 | $37.1K | Form 4 |
| Mar 26, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Purchase | 2,601 | $28.85 | $75K | Form 4 |
| Mar 26, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Purchase | 1,025 | $29.98 | $30.7K | Form 4 |
| Mar 26, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Sale | 583 | $26.88 | $15.7K | Form 4 |
| Mar 26, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Sale | 1,274 | $28.69 | $36.6K | Form 4 |
| Mar 26, 2026 | Ics Opportunities Ii Llc +3 | 10% owner | Purchase | 778 | $27.23 | $21.2K | Form 4 |
| Dec 9, 2025 | Cambrian BioPharma Inc | 10% owner | Sale | 3,105 | $8.59 | $26.7K | Form 4 |
| Dec 9, 2025 | Cambrian BioPharma Inc | 10% owner | Sale | 446 | $7.92 | $3.5K | Form 4 |
| Dec 9, 2025 | Cambrian BioPharma Inc | 10% owner | Sale | 395 | $8.04 | $3.2K | Form 4 |
| Dec 9, 2025 | Cambrian BioPharma Inc | 10% owner | Sale | 2,666 | $7.95 | $21.2K | Form 4 |
| Dec 8, 2025 | James Peyer | 10% owner | Sale | 3,105 | $8.59 | $26.7K | Form 4 |
| Dec 5, 2025 | Cambrian BioPharma Inc | 10% owner | Sale | 14,508 | $11.40 | $165K | Form 4 |
| Dec 5, 2025 | Cambrian BioPharma Inc | 10% owner | Sale | 42 | $13.16 | $553 | Form 4 |
| Dec 5, 2025 | Cambrian BioPharma Inc | 10% owner | Sale | 1,745 | $12.29 | $21.4K | Form 4 |
| Dec 4, 2025 | Cambrian BioPharma Inc | 10% owner | Sale | 5,000 | $9.06 | $45.3K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Ics Opportunities Ii Llc | 10% owner | $960K | $627K | Apr 7, 2026 |
| Brian C Stephenson | Chief Financial Officer | $1.1M | – | Jul 1, 2026 |
| Cambrian BioPharma Inc | 10% owner | – | $788K | Jun 1, 2026 |
| Millennium Management Llc | 10% owner | $382K | $77K | Apr 1, 2026 |
| Anand Kiran Parikh | President and CEO, Director | $55.4K | – | Jun 22, 2026 |
| James Peyer | 10% owner | – | $26.7K | Dec 8, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
FTH short interest
High short interest. 10.6% of FTH shares are sold short: about 1 share in 9. Over the last 9 reports the number of shares short went up 250%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 2.73M FTH shares were sold short, 10.6% of the shares outstanding, up 17.7% from the report before. At the average daily volume of 432,468 shares, buying them all back would take about 6.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 2.73M | 10.57% | +18% | 432,468 | 6.3 |
| Oct 15, 2026 | 2.32M | 8.98% | +12% | 297,820 | 7.8 |
| Sep 30, 2026 | 2.07M | 8.00% | +57% | 569,389 | 3.6 |
| Sep 15, 2026 | 1.32M | 5.10% | +20% | 301,783 | 4.4 |
| Aug 31, 2026 | 1.10M | 4.25% | +33% | 299,621 | 3.7 |
| Aug 14, 2026 | 827,167 | 3.20% | +1% | 300,902 | 2.8 |
| Jul 31, 2026 | 815,587 | 3.16% | -8% | 289,922 | 2.8 |
| Jul 15, 2026 | 890,306 | 66.43% | +14% | 235,950 | 3.8 |
| Jun 30, 2026 | 780,396 | 58.23% | +27% | 112,285 | 7.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Faeth Therapeutics company events
Faeth Therapeutics filed 18 reports on Form 8-K in the last 12 months, 9 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026AnnouncementFaeth Therapeutics, Inc. made available a presentation to be used to discuss, among other things, the topline clinical data from the Company’s Phase 2 PIK-201 trial evaluating PIKTOR in patients with advanced endometrial cancer. Filing
- Nov 9, 2026AnnouncementShared information with investors. Filing
- Nov 3, 2026ResultsReleased financial results. Filing
- Oct 27, 2026LeadershipThe Board of Directors of Faeth Therapeutics, Inc. increased the size of the Board from six to seven directors and appointed Adam Schayowitz to serve as a Class III director, effective immediately. Filing
- Sep 17, 2026LeadershipThe Board of Directors of Faeth Therapeutics, Inc. increased the size of the Board from five to six directors and appointed Karen Vousden, Ph.D. to serve as a Class II director, effective immediately. Filing
- Aug 4, 2026ResultsReleased financial results. Filing
- Jul 23, 2026LeadershipThe Board of Directors of Faeth Therapeutics, Inc., upon the recommendation of the Compensation Committee of the Board, approved one-time supplemental grants of performance-based stock options under the Company’s 2026 Equity Incentive Plan to current employees of the Company who were employed with… Filing
- Jun 18, 2026AgreementFaeth Therapeutics, Inc. entered into a Sales Agreement with TD Securities (USA) LLC, pursuant to which the Company from time to time may offer and sell shares of its common stock, par value $0.0001 per share, through or to the Agent. Filing
- Jun 15, 2026LeadershipDeparture of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
- Jun 10, 2026LeadershipSensei Biotherapeutics, Inc. held its 2026 annual meeting of stockholders. Filing
- May 22, 2026AnnouncementSensei Biotherapeutics, Inc. announced an update regarding the expected reconstitution of the board of directors of the Company in connection with the Company’s 2026 Annual Meeting of Stockholders to be held on June 10, 2026, as described in the Company’s definitive proxy statement filed with the… Filing
- May 21, 2026AnnouncementAs previously announced, Sensei Biotherapeutics, Inc. will hold its 2026 annual meeting of stockholders of the Company on June 10, 2026, at 11:00 a.m. Filing
- May 15, 2026ResultsReleased financial results. Filing
- Apr 16, 2026LeadershipEach of Christopher W. Gerry, Thomas Ricks, and Kristian Humer tendered conditional resignations from the Board of Directors of Sensei Biotherapeutics, Inc., in each case effective as of two business days following the conclusion of the Company’s Annual Meeting of Stockholders to be held on June… Filing
- Mar 30, 2026ResultsReleased financial results. Filing
- Feb 18, 2026LeadershipAppointment of Directors In accordance with the Merger Agreement, on February 17, 2026, effective immediately after the First Effective Time, Anand Parikh was appointed to the Board as a Class I director of the Board. Filing
- Feb 13, 2026LeadershipThe board of directors of Sensei Biotherapeutics, Inc. voted to increase the size of the Board from three members to five members and to appoint Christopher W. Gerry and Phillip B. Donenberg as new directors to fill the resulting vacancy, effective immediately, for a term until each of their… Filing
- Dec 23, 2025LeadershipSensei Biotherapeutics, Inc. entered into Retention Agreements with Christopher Gerry, its President and Principal Executive Officer, and Josiah Craver, its Senior Vice President of Finance and Principal Finance and Accounting Officer, which amend in part the compensatory provisions of their… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Faeth Therapeutics financials
Famous investors that hold FTH
3 of the 50 well-known investors we track reported holding FTH in their latest 13F filing. The largest position is Ken Griffin's, worth $13.4M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 450,626 | $13.4M | 0.0% | +3565% |
| Israel Englander · Millennium Management | Q3 2026 | 29,002 | $863K | 0.0% | New |
| Jim Simons · Renaissance Technologies | Q3 2026 | 8,725 | $259K | 0.0% | -57% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named FTH in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Avoro Capital Advisors LLC | 13G | 5.5% |
| Nov 16, 2026 | Avoro Capital Advisors LLC | 13G | 5.5% |
| Nov 13, 2026 | Montanova Capital, LLC | 13G/A | 8.9% |
| Nov 13, 2026 | Montanova Capital, LLC | 13G/A | 8.9% |
Questions about Faeth Therapeutics, Inc. (FTH) stock
Who owns the most FTH stock?
The largest reported owner of Faeth Therapeutics, Inc. (FTH) is Montanova Capital, LLC, with 7.8% of the company. In total, 44 funds and institutions reported holding FTH at the end of Q2 2026, together about 50% of the shares. See the largest owners.
Are FTH insiders buying or selling?
In the last 12 months, FTH insiders reported 49 open-market purchases worth $2.5M and 36 sales worth $1.5M. The latest trade was on Jul 1, 2026. See every trade.
What is the short interest in FTH?
As of Oct 30, 2026, 2.73M FTH shares were sold short, 10.6% of the shares outstanding, up 17.7% from the report before. At the average daily volume of 432,468 shares, buying them all back would take about 6.3 trading days (days to cover). See the history.
Which famous investors hold FTH?
3 of the 50 well-known investors we track reported FTH in their latest 13F filing, including Ken Griffin, Israel Englander, Jim Simons. The largest position is worth $13.4M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.